Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) gapped down before the market opened on Wednesday . The stock had previously closed at $84.57, but opened at $72.90. Dianthus Therapeutics shares last traded at $72.07, with a volume of 790,177 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DNTH. William Blair reissued an “outperform” rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th. Raymond James Financial reiterated a “strong-buy” rating on shares of Dianthus Therapeutics in a report on Wednesday. Wedbush increased their price objective on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Jefferies Financial Group set a $98.00 price objective on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Stock Up 0.0%

The stock’s 50 day moving average price is $87.15 and its 200-day moving average price is $64.95. The stock has a market capitalization of $4.18 billion, a PE ratio of -18.51 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.22. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. As a group, sell-side analysts predict that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at $362,480. This represents a 86.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ryan Savitz sold 114,367 shares of the stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $83.00, for a total value of $9,492,461.00. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 149,121 shares of company stock worth $12,635,454. Corporate insiders own 3.02% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after acquiring an additional 406,254 shares in the last quarter. Patient Square Capital LP bought a new position in Dianthus Therapeutics during the 3rd quarter worth about $4,919,000. UBS Group AG grew its holdings in Dianthus Therapeutics by 342.6% during the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after acquiring an additional 469,547 shares in the last quarter. SG Americas Securities LLC purchased a new position in Dianthus Therapeutics during the 4th quarter valued at about $765,000. Finally, Fairmount Funds Management LLC increased its position in Dianthus Therapeutics by 22.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after purchasing an additional 600,000 shares during the period. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.